News and Trends 30 Apr 2018 Record Series B Financing Supports Antibody Cancer Therapy Crescendo Biologics has raised €57M in in the largest disclosed Series B financing in the European biotech sector this year. The company will use the funds to develop its antibody cancer treatment that activates white blood cells to fight tumors. Crescendo Biologics, based in Cambridge, UK, has raised €57M in the largest disclosed Series B financing for the European […] April 30, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Apr 2018 The 5 Best-Selling European Drugs of 2017 Biologicals have completely changed the way we treat diseases, and their growth has exploded in the last two decades. Not surprisingly, they took a whopping 7 out of 15 spots on the list of 2017’s best selling drugs globally. We were of course keen to find out how European-derived drugs faired out in this list. […] April 30, 2018 - 7 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
Startup Scout 27 Apr 2018 This Portuguese Biotech is Developing a Faster Antimicrobial Susceptibility Test Today, we’re in Matosinhos, Portugal, visiting FASTinov, a biotech that is developing an antimicrobial susceptibility test that are faster than standard assays. The technology could help battle antibiotic resistance by identifying appropriate treatments. Mission: Founded in 2013, FASTinov is developing a new type of test for antimicrobial susceptibility that can help combat the global health problem of antibiotic […] April 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2018 Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US Pluristem Therapeutics will start a Phase III trial this year in the US for its pioneering cell therapy that uses placenta cells to restore muscle injuries. Pluristem Therapeutics, an Israeli biotech and world-leader in cell therapies, has received a green light from the FDA to start a Phase III study in the US. The trial will test […] April 26, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2018 Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, the first treatment of its kind, for advanced solid tumors. The news follows the Phase […] April 25, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 25 Apr 2018 Planting the Seeds to Grow the Italian Biotech Industry Many European countries, including the UK, France, Germany, and Switzerland, boast a thriving biotech industry. Others are still a step behind when it comes to industrializing their research. Let’s take a look at how Italy is pushing through to make it to the first league. Italy is certainly a pioneer and leader in life science research — […] April 25, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 Fundraising Boosts Italian Red Blood Cell Therapy EryDel has raised €26.5M to develop a red blood cell drug delivery system to treat a rare disease of the immune and nervous systems. Italian biotech EryDel has raised €26.5M to complete a Phase III trial testing a unique technology to treat ataxia telangiectasia, a rare genetic disorder. The fundraising was led by Sofinnova Partners, a leading European venture […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2018 New Class of Antibiotics Combats the Three Deadliest Bacteria in the World A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no […] April 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 24 Apr 2018 Can DIY Biology Ever Become a Big Player in Biotech? Alongside university research and industry R&D, a third, parallel community actively uses tools and methods of the life sciences: biohackers. What are they, and what is their impact on biotech and the startup scene? One of the richest persons alive and one of the first hackers ever, Bill Gates, said that if he were young today […] April 24, 2018 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2018 The First CAR-T Therapy Is Not Living Up to Commercial Expectations Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […] April 23, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2018 Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. The company plans to file for an EU approval of its treatment later this year. US firm bluebird bio has results from two clinical studies showing its LentiGlobin gene […] April 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2018 Major $115M Fundraising Fuels AI Drug Development BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities of its artificial intelligence technology. The technology could significantly increase the speed and efficiency of the drug discovery process. BenevelontAI, based in London, has raised an impressive $115M (€93M) to advance its use of AI in drug development. The funding, raised from […] April 19, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email